Association between nonalcoholic fatty liver disease and epicardial adipose tissue: A Meta-analysis

Wang XiangHong; Ma BaoHua; Zou XiuLan; Yao KeCheng; He Qian

doi:10.3969/j.issn.1001-5256.2020.06.023

Volume 36 Issue 6

Jun. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(6): 1304-1309

PDF( 3036 KB)

Association between nonalcoholic fatty liver disease and epicardial adipose tissue: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2020.06.023

Research funding:

Published Date: 2020-06-20

Abstract

Abstract

Objective To investigate the association between nonalcoholic fatty liver disease( NAFLD) and epicardial adipose tissue( EAT). Methods Databases including PubMed,Embase,Web of Science,Wanfang Data,and CNKI were searched for the articles on the association of thickness and volume of EAT with NAFLD published up to January 1,2019. Stata12. 0 was used to calculate standardized mean difference( SMD) and 95% confidence interval( CI); the I2 test was used to evaluate heterogeneity between studies,and sensitivity analysis and subgroup analysis were used to explore the source of heterogeneity. Results A total of 13 articles were included,with 4672 subjects in total( 2586 subjects in the normal control group and 2086 subjects in the NAFLD group). The NAFLD group had a significant increase in EAT compared with the normal control group( SMD = 0. 58,95% CI: 0. 39-0. 77,P < 0. 001). There were significant differences between the NAFLD group and the normal control group in the thickness and volume of EAT( thickness: SMD = 0. 61,95% CI:0. 40-0. 83,P < 0. 001; volume: SMD = 0. 47,95% CI: 0. 17-0. 76,P = 0. 002). As for the Asian population,compared with the normal control group,the NAFLD group had a significant increase in EAT( SMD = 0. 37,95% CI: 0. 06-0. 68,P = 0. 018); as for the European/American population,compared with the normal control group,the NAFLD group had a significant increase in EAT( SMD = 0. 66,95% CI: 0. 40-0. 92,P < 0. 001). Compared with the normal control group,the NAFLD patients aged ≥50 years had a significant increase in EAT( SMD = 0. 46,95% CI: 0. 31-0. 62,P < 0. 001); there was a significant difference in EAT between the NAFLD patients aged < 50 years and the normal control group( SMD = 0. 72,95% CI: 0. 37-1. 06,P < 0. 001). The NAFLD patients with a body mass index( BMI) of ≥30 kg/m2 had significantly thicker EAT than the normal control group( SMD = 0. 79,95% CI: 0. 43-1. 15,P < 0. 001); the NAFLD patients with a BMI of < 30 kg/m2 also had significantly thicker EAT than the normal control group( SMD = 0. 42,95% CI: 0. 21-0. 62,P < 0. 001). Compared with the normal control group,the NAFLD patients undergoing radiological examination had a significant increase in EAT( SMD = 0. 44,95% CI: 0. 26-0. 63,P < 0. 001); compared with the normal control group,the NAFLD patients undergoing liver biopsy also had a significant increase in EAT( SMD = 1. 05,95% CI: 0. 82-1. 29,P < 0. 001). Publication bias was assessed by funnel plots( symmetric),Begg's test( P = 0. 583),and the Egger's test( P = 0. 126),and the results showed high reliability. Conclusion NAFLD is significantly associated with EAT cardiovascular risk factors,which will help NAFLD patients to establish effective strategies for the prevention and control of cardiovascular events.
- non-alcoholic fatty liver disease,
- pericardium,
- Meta-analysis as topic

FullText(HTML)

References(33)

References

[1] FOTBOLCU H,YAKAR T,DUMAN D,et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease[J]. Cardiol J,2010,17(5):457-463.

[2] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol,2018,34(12):2515-2519.(in Chinese)李婕．亚洲地区非酒精性脂肪性肝病的流行病学特点[J]．临床肝胆病杂志，2018,34(12):2515-2519.

[3] ANGULO P. GI epidemiology:Nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther,2007,25(8):883-889.

[4] MUSSO G,GAMBINO R,BO S,et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects[J].Diabetes Care,2008,31(3):562-568.

[5] SOOKOIAN S,BURGUEO AL,CASTAO G,et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment panel III criteria in nonobese nondiabetic subjects:Response to Musso et al[J]. Diabetes Care,2008,31(5):e42-e43.

[6] DOWMAN JK,TOMLINSON JW,NEWSOME PN. Pathogenesis of non-alcoholic fatty liver disease[J]. QJM,2010,103(2):71-83.

[7] AMPUERO J,GALLEGO-DURN R,ROMERO-GMEZ M.Association of NAFLD with subclinical atherosclerosis and coronary-artery disease:Meta-analysis[J]. Rev Esp Enferm Dig,2015,107(1):10-16.

[8] CHEUNG CL,LAM KS,WONG IC,et al. Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA[J]. BMC Med,2014,12:154.

[9] IACOBELLIS G,CORRADI D,SHARMA AM. Epicardial adipose tissue:Anatomic,biomolecular and clinical relationships with the heart[J]. Nat Clin Pract Cardiovasc Med,2005,2(10):536-543.

[10] IACOBELLIS G,BIANCO AC. Epicardial adipose tissue:Emerging physiological, pathophysiological and clinical features[J]. Trends Endocrinol Metab,2011,22(11):450-457.

[11] CHO KI,JO EA,CHO SH,et al. The influence of epicardial fat and nonalcoholic fatty liver disease on heart rate recovery in metabolic syndrome[J]. Metab Syndr Relat Disord,2017,15(5):226-232.

[12] PSYCHARI SN,REKLEITI N,PAPAIOANNOU N,et al. Epicardial fat in nonalcoholic fatty liver disease:Properties and relationships with metabolic factors,cardiac structure,and cardiac function[J]. Angiology,2016,67(1):41-48.

[13] OGˇUZ D，NAL H，EROGˇLU H,et al. Aortic flow propagation velocity,epicardial fat thickness,and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease[J]. Anatol J Cardiol,2016,16(12):974-979.

[14] SUNBUL M,AGIRBASLI M,DURMUS E,et al. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness[J]. Atherosclerosis,2014,237(2):490-493.

[15] IACOBELLIS G,BARBARINI G,LETIZIA C,et al. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects[J]. Obesity(Silver Spring),2014,22(2):332-336.

[16] ALP H,KARAARSLAN S,SELVER EKLIOGˇLU B,et al. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents[J]. Can J Cardiol,2013,29(9):1118-1125.

[17] COLAK Y,KARABAY CY,TUNCER I,et al. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol,2012,24(6):613-618.

[18] YILMAZ Y,KURT R,GURDAL A,et al. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease[J]. Atherosclerosis,2011,217(1):125-129.

[19] KIM BJ,CHEONG ES,KANG JG,et al. Relationship of epicardial fat thickness and nonalcoholic fatty liver disease to coronary artery calcification:From the CAESAR study[J]. J Clin Lipidol,2016,10(3):619-626. e1.

[20] FRACANZANI AL,PISANO G,CONSONNI D,et al. Epicardial adipose tissue(EAT)thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease[J]. PLo S One,2016,11(9):e0162473.

[21] BROUHA SS,NGUYEN P,BETTENCOURT R,et al. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes:A prospective study[J]. Eur Radiol,2018,28(4):1345-1355.

[22] GRANR M,NYMAN K,SIREN R,et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease[J]. Circ Cardiovasc Imaging,2015,8(1):e001979.

[23] CHEN ZH,YANG WJ,YAN FH. The correlation of visceral adipose tissue volume and other rontine obesity indexes with nonalcoholic fatty liver disease[J]. Radiol Pract,2017,32(5):436-440.(in Chinese)陈炽华，杨文洁，严福华．内脏脂肪体积及常见肥胖指标与非酒精性脂肪肝的相关性研究[J]．放射学实践，2017,32(5):436-440.

[24] LONARDO A,SOOKOIAN S,PIROLA CJ,et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease[J].Metabolism,2016,65(8):1136-1150.

[25] TARGHER G. Non-alcoholic fatty liver disease as driving force in coronary heart disease?[J]. Gut,2017,66(2):213-214.

[26] TARGHER G,BYRNE CD,LONARDO A,et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A meta-analysis[J]. J Hepatol,2016,65(3):589-600.

[27] LI Q,ZHUO QB,CHEN L,et al. Research advances in association between non-alcoholic fatty liver disease and cardiovascular disease[J]. J Clin Hepatol,2015,31(7):1046-1049.(in Chinese)李强，卓其斌，陈良，等．非酒精性脂肪性肝性与心血管疾病的相关性[J]．临床肝胆病杂志，2015,31(7):1046-1049.

[28] FAN Y,WEI F,ZHOU Y,et al. Association of non-alcoholic fatty liver disease with impaired endothelial function by flowmediated dilation:A meta-analysis[J]. Hepatol Res,2016,46(3):e165-e173.

[29] SOOKOIAN S,PIROLA CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis:A systematic review[J]. J Hepatol,2008,49(4):600-607.

[30] MARCHESINI G,BRIZI M,BIANCHI G,et al. Nonalcoholic fatty liver disease:A feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850.

[31] GRUZDEVA OV,AKBASHEVA OE,DYLEVA YA,et al. Adipokine and cytokine profiles of epicardial and subcutaneous adipose tissue in patients with coronary heart disease[J]. Bull Exp Biol Med,2017,163(5):608-611.

[32] DU YY,LIU Y,LU M,et al. Expressions of adiponectin-related miR-371b-5p in epicardial adipose tissue and plasma of patients with coronary heart disease and its effect on secretion of adipocytokines[J]. J Jilin Univ(Med Edit),2019,45(3):643-650,after insert 6.(in Chinese)杜雅彦，刘洋，卢沐，等．冠心病患者心外膜脂肪组织和血浆中脂联素相关miR-371b-5p表达及其对脂肪细胞因子分泌的影响[J]．吉林大学学报(医学版)，2019,45(3):643-650，后插6.

[33] EROGˇLU S,SADE LE,YILDIRIR A,et al. Epicardial adipose tissue thickness by echocardiography is a marker for the presence and severity of coronary artery disease[J]. Nutr Metab Cardiovasc Dis,2009,19(3):211-217.

Relative Articles

[1]	Guojing XING, Lifei WANG, Longlong LUO, Xiaofeng ZHENG, Chun GAO, Xiaohui YU, Jiucong ZHANG. Role of autophagy in treatment of paracetamol-induced liver injury[J]. Journal of Clinical Hepatology, 2025, 41(2): 389-394. doi: 10.12449/JCH250229
[2]	Rongzhi WANG, Linli WANG, Jingwen JIAO, Yunfei YU, Baolong LI. Research advances in the degradation of hepatic lipid droplets through the autophagy pathway[J]. Journal of Clinical Hepatology, 2024, 40(9): 1916-1923. doi: 10.12449/JCH240931
[3]	Runbing ZHANG, Tingting SHI, Yang WU, Jiucong ZHANG, Xiaofeng ZHENG. The mechanism of autophagy inducing drug resistance of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(11): 2315-2319. doi: 10.12449/JCH241128
[4]	Xuanxuan KOU, Hua ZHANG, Jingxin DENG, Jiangang ZHANG. Role of intrahepatic microenvironment induced-autophagy in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(6): 1440-1445. doi: 10.3969/j.issn.1001-5256.2023.06.029
[5]	Yangyang HU, Xing ZHANG, Yue LUO, Yadong WANG, Caiyan ZHAO. Advances in the protective mechanism and clinical implications of autophagy in liver failure[J]. Journal of Clinical Hepatology, 2023, 39(10): 2485-2490. doi: 10.3969/j.issn.1001-5256.2023.10.030
[6]	Zhen LI, Ke WANG, Kaiqiang WANG, Kexian YU. Research advances in targeting autophagy to alleviate hepatic ischemia-reperfusion injury[J]. Journal of Clinical Hepatology, 2022, 38(1): 210-214. doi: 10.3969/j.issn.1001-5256.2022.01.037
[7]	Jiahe ZHAO, Xinyu MA, Jingya XU, Tingting DUAN, Chunlei ZHANG, Baolong LI. Research advances in related factors for autophagy in the regulation of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1713-1717. doi: 10.3969/j.issn.1001-5256.2021.07.050
[8]	Qianlan DAI, Shaoneng LIU. Role of autophagy in liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(6): 1440-1444. doi: 10.3969/j.issn.1001-5256.2021.06.046
[9]	HUANG Qing, LI JingTao, LIU YongGang, WEI HaiLiang, YAN ShuGuang, GUO YingJun, CHANG ZhanJie. Regulatory effect of mTOR pathway-mediated autophagy in liver injury[J]. Journal of Clinical Hepatology, 2020, 36(11): 2621-2625. doi: 10.3969/j.issn.1001-5256.2020.11.051
[10]	Wang YuLu, Xu XiaoYang, Yu XiaoHan, Ping Jian, Zhao ChangQing. Role of oxidative stress and autophagy in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(2): 426-429. doi: 10.3969/j.issn.1001-5256.2020.02.042
[11]	Gong Jing, Jie XinKe. Effect of endoplasmic reticulum stress and autophagy on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2019, 35(12): 2828-2832. doi: 10.3969/j.issn.1001-5256.2019.12.041
[12]	Gu Huan, Bai ZhangChuan, Liu Liu, Cheng QiuLuo, Zhu Ying. Research advances in traditional Chinese medicine regulation of autophagy in treatment of liver cancer[J]. Journal of Clinical Hepatology, 2019, 35(11): 2582-2587. doi: 10.3969/j.issn.1001-5256.2019.11.043
[13]	Wang MuQi, Li YaPing, Liu LaYang, Dang ShuangSuo, Shi JuanJuan, Jia XiaoLi. Role and mechanism of autophagy in development and progression of hepatocellular carcinoma and regulation of immunotherapy[J]. Journal of Clinical Hepatology, 2019, 35(5): 1129-1134. doi: 10.3969/j.issn.1001-5256.2019.05.045
[14]	Shi HongBo, Shi HongLin, Zhang XiangYing, Chen DeXi, Duan ZhongPing, Ren Feng. Protective effect of autophagy in mice with acute liver injury induced by D- galactosamine / lipopolysaccharide and related mechanisms[J]. Journal of Clinical Hepatology, 2017, 33(2): 329-333. doi: 10.3969/j.issn.1001-5256.2017.02.027
[15]	Yan Rong, Niu ChunYan, Yu Lu, Tian Yu. Interaction between autophagy and lipid metabolism in cell models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(10): 1981-1986. doi: 10.3969/j.issn.1001-5256.2017.10.027
[16]	Han WeiJia, Shi HongBo, Chen Yu. Research progress in the role of autophagy in liver regeneration[J]. Journal of Clinical Hepatology, 2016, 32(9): 1827-1831. doi: 10.3969/j.issn.1001-5256.2016.09.044
[17]	Wang WeiHao, Xu WeiHua. Roles of Nrf2 and autophagy in liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 447-451. doi: 10.3969/j.issn.1001-5256.2015.03.033
[18]	Huang LanYu, Xu LieMing. Relationship between liver diseases and autophagy[J]. Journal of Clinical Hepatology, 2014, 30(2): 186-188. doi: 10.3969/j.issn.1001-5256.2014.02.022
[19]	Ding JianBo, Li XiuHui. Current perspectives on the role of autophagy in liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(4): 305-307.
[20]	Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 彭佳丽，赖欣，韦嘉. 自噬在HBV及相关肝脏疾病中的双重作用. 临床肝胆病杂志. 2018(10): 2217-2220 . 本站查看
Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1084) PDF downloads(190)

Association between nonalcoholic fatty liver disease and epicardial adipose tissue: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2020.06.023

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(2)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Association between nonalcoholic fatty liver disease and epicardial adipose tissue: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2020.06.023

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(2)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content